ADMA ADMA Biologics Inc
Company Analysis
Latest News
🟢 ADMA Biologics is trading 25% up after raising full-year adjusted earnings outlook
ADMA Biologics is trading at $13.09 (+24.90%) on November 5 after reporting third-quarter results and raising its full-year adjusted earnings outlook. -...
🟢 ADMA Biologics is trading 22.23% up in pre-market after stronger third-quarter results and raised profit outlook
ADMA Biologics is trading at $12.81, up 22.23% in pre-market on November 5 after its third-quarter report, released after the November 4 close, raised minimum...
ADMA Biologics Surges 27% on a Blowout Quarter — But Can Its Star Drug Carry the Whole Company?
Shares vaulted 27.5% after hours as ADMA Biologics reported third-quarter results that snapped a streak of disappointments, raising an urgent question: whether...
🟢 ADMA Biologics is trading 27.48% up in after-hours trading after Q3 revenue beat
ADMA Biologics is trading at $13.36, up 27.48%, in after-hours trading after Q3 revenue beat expectations. - The price followed the November 4, 2026...
ADMA Biologics third quarter 2026 revenue of $141M beat estimates behind 31% Asceniv growth
ADMA Biologics reported total revenue of $141.1 million for the third quarter 2026, surpassing analyst expectations of $139.8 million. The results were driven...
🔴 ADMA Biologics is trading 5% down; no confirmed catalyst identified
ADMA Biologics is trading at $10.57 (-4.82%), and the reason for the November 4 decline remains unclear. - No confirmed company-specific announcement...
ADMA Biologics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
ADMA Biologics is expected to report Q3 2026 consensus revenue of $139.8 million (+4.16% YoY) and EPS of $0.19 (+18.75% YoY), with its stock currently trading...
🔴 ADMA Biologics is trading 6.13% down in pre-market
ADMA Biologics is trading 6.13% down at $10.71 ahead of the November 2, 2026 market open. No clear company-specific announcement explaining the decline...
🟢 ADMA Biologics is trading 4.07% up today amid higher U.S. indexes
ADMA Biologics is trading 4.07% higher at $11.12 on October 26, 2026, with higher U.S. indexes potentially supportive; no direct cause has been established. -...
🟢 ADMA Biologics is trading 4.03% up today amid biotech and broader-market strength
ADMA Biologics is trading at $11.11, up 4.03%, alongside biotech and broader-market strength; no new company announcement or clearly confirmed company-specific...
🟢 ADMA Biologics is trading 5.3% up in pre-market with catalyst unconfirmed
ADMA Biologics is trading at $11.30 (+5.31%) in pre-market; the cause of the move remains unconfirmed. - On October 15, the company announced peer-reviewed...
🟢 ADMA Biologics is trading 4.1% up today amid study reporting IVIG impurity removal
ADMA Biologics is trading 4.11% higher at $10.77 alongside study news; the release did not explicitly link it to the share-price move. - On October 15, 2026, a...
🟢 ADMA Biologics is trading 4.22% up
ADMA Biologics is trading at $10.13, up 4.22%, with the specific driver of the gain unclear. - No clear company-specific catalyst was found for October 5,...
🟢 ADMA Biologics is trading 4.1% up
ADMA Biologics is trading at $9.77, up 4.10%; the reason for the September 28 gain remains unclear. - The company’s investor-relations releases list no...
🟢 ADMA Biologics is trading 54% up in after-hours trading; catalyst remains unclear
ADMA Biologics is trading 54% higher at $15.15 after-hours on September 22, 2026; no company-specific catalyst has been identified. - The move follows a...
🟢 ADMA Biologics is trading 4.23% up today as major indexes rise
ADMA Biologics is trading +4.23% at $9.49 amid a broad September 21, 2026 risk-on rally. • The S&P 500, Nasdaq, and Dow Jones are all higher, supporting...
🔴 ADMA Biologics is trading 5% down today after board-breach investigation announcement
ADMA Biologics is trading 5.25% down now at $8.66 after Berger Montague announced a September 14, 2026 investigation into potential board breaches tied to...
ADMA Biologics Faces Investor Investigation Over Allegations of Misleading Statements and Breaches of Fiduciary Duties
ADMA Biologics is the subject of an investigation announced by the Shareholders Foundation, Inc. on behalf of long-term investors. The probe centers on...
ADMA Biologics Downgraded, Facing BIVIGAM Slump and Lowered 2026 Guidance
Analysts downgraded ADMA Biologics to a Hold rating on September 2, 2026. The move follows a deceleration in growth and a reduction in revenue guidance for...
BlackRock's 16.5% Stake in ADMA Biologics Signals Big-Money Confidence, but Can a Plasma Drug Company Justify the Hype?
Shares of ADMA Biologics surged 9.2% to $10.20 on August 31, bucking a softer broader market, after BlackRock disclosed ownership of roughly 38.4 million...